Shares of AgeX Therapeutics (NYSE: $AGE) closed at $2.48 Thursday evening, up 195% from the previous day following news of a significant stake from Juvenescence – Hitting IBR’s target.
The Company’s shares jumped as much as 450% on Thursday October 8 – four months after IBR’s analysis and strong buy recommendation.
The target share price of $2.50 has been hit.
That is a solid 166% return – or 322% if you managed to sell at the top.
A few months ago, in a comprehensive report on AgeX Therapeutics, IBR recommended a strong buy due to the company’s huge potential and stellar management.
Juvenescence announced it had obtained a 50% stake in AgeX Therapeutics.
Our favorite saying applies: ‘The pigs get fed and the hogs get slaughtered” – Don’t be afraid to take some profits off the table.